Parallel Mass Spectrometer Boosts Protein & Metabolite Detection

Researchers have unveiled a prototype mass spectrometer capable of trapping around 1,000 times more ions than state-of-the-art commercial instruments, potentially revolutionizing fields like proteomics, and metabolomics. The advance, inspired by the structure of cell nuclei, addresses a long-standing limitation in mass spectrometry: the bottleneck created by traditional ion trap designs.

Mass spectrometry, a technique used to identify and quantify molecules by measuring their mass-to-charge ratio, has become indispensable in a wide range of scientific disciplines. Since its inception around 1913 with J.J. Thomson’s initial design, the technology has steadily improved in sensitivity and size, but has largely remained a serial process, analyzing ions one at a time, according to Brian Chait, a physicist at The Rockefeller University in New York City.

Conventional mass spectrometers utilize ion traps – chambers that hold ions for analysis. These traps typically feature a single inlet and outlet, creating a constraint that forces researchers to prioritize which ions to analyze. “It’s like trying to catch a fish from Niagara Falls with a single bucket,” Chait explained. Important molecules, particularly those present in low abundance, can be missed during this selective process.

Chait and his colleague, Andrew Krutchinsky, sought inspiration in the biological world, specifically the cell nucleus. The nucleus employs numerous openings to facilitate the movement of molecules in and out. Over a decade, the researchers developed and tested various prototypes with configurations ranging from 6 to over 1,000 ports. The current prototype, dubbed MultiQ-IT, incorporates 486 openings.

The increased number of ports allows for a more parallel analysis of ions. The MultiQ-IT device can trap significantly more ions while also manipulating electrical fields to expel high-abundance ions – those that provide less unique information – thereby enhancing sensitivity. This capability could allow scientists to identify rare but functionally important proteins that might otherwise be overlooked.

“This approach, in general, is inspired,” said David Clemmer, a chemist at Indiana University in Bloomington, who was not involved in the research. “Nature doesn’t stop and select things one at a time to seem at. It does things all at once all the time.” He described the work as achieving a “truly parallel mass analyzer,” offering researchers the “chance for true discovery” by eliminating the need for pre-selection of analytes.

The ability to detect low-abundance proteins is crucial because the quantity of a protein does not necessarily correlate with its importance. “There is no correlation between the amount of a protein and its importance,” Chait stated. Parallelization, mirroring advancements in genomics and computing, could unlock new insights into the proteome – the entire set of proteins expressed by an organism.

While the prototype demonstrates the feasibility of parallelization in mass spectrometry, further research is needed to manage and interpret the increased data output. The team acknowledges that handling the complex data streams generated by the MultiQ-IT device presents a significant challenge.

Recent advancements in mass spectrometry extend beyond this parallelization approach. In October, Waters Corporation launched a charge detection mass spectrometer (CDMS) based on technology developed by Clemmer’s colleague, Martin Jarrold, at Indiana University. Jarrold and Clemmer co-founded Megadalton Solutions, which was acquired by Waters in 2022, to commercialize the CDMS technology.

Clemmer suggests that combining the parallelization offered by the MultiQ-IT with the ability of CDMS to measure large molecular complexes, such as protein machines, could accelerate progress in the field. “There’s kind of an immediate 10 to 20-year horizon where we start to be able to deal with biological complexity at the next level,” he said, potentially leading to a more comprehensive understanding of the molecular pathways underlying life.